

SHORT COMMUNICATION

2-*O*-Acetyl-3,4,5,6-tetra-*O*-benzyl-*D*-*myo*-inosityl diphenylphosphate: A new useful intermediate to inositol phosphate and phospholipids

Sara Sangiorgio¹ | Mattia Cambò¹ | Riccardo Semproli² | Daniela Ubiali² |
Giovanna Speranza¹ | Marco Rabuffetti¹ 

¹Department of Chemistry, University of Milan, Milan, Italy

²Department of Drug Sciences, University of Pavia, Pavia, Italy

Correspondence

Marco Rabuffetti, Department of Chemistry, University of Milan, Via Golgi 19, 20133 Milan, Italy.
Email: marco.rabuffetti1@unimi.it

Funding information

Innovhub-SSI; Cariplo Foundation, Grant/Award Number: 2017-0978

Abstract

Inositol phosphates and inositol phospholipids are ubiquitous in biochemistry and play a central role in cell signaling and regulation events. For this reason, their synthesis has attracted widespread interest. This paper describes the preparation of a new optically active inositol phosphate derivative, 2-*O*-acetyl-3,4,5,6-tetra-*O*-benzyl-*D*-*myo*-inosityl diphenylphosphate (**6**), and its characterization by spectroscopic methods. Compound (**6**) represents a useful intermediate for the preparation of inositol phosphate and phospholipids, in particular of glycerophosphoinositol (GPI), a natural anti-inflammatory agent.

KEYWORDS

anti-inflammatory activity, desymmetrization, *L*-camphor dimethyl acetal, *myo*-inositol phosphate, *myo*-inositol phospholipids

1 | INTRODUCTION

The inositols are the nine stereoisomeric forms of cyclohexanehexol belonging to the class of cyclitols, that is, cycloalkanes in which three or more ring atoms are each substituted with one hydroxyl group.^{1,2} *myo*-Inositol, or *cis*-1,2,3,5-*trans*-4,6-cyclohexanehexol, is the most common isomeric form in nature that also uses at least five of the others (*scyllo*-, *epi*-, *neo*-, *D-chiro*-, and *muco*-inositols).³ It constitutes the structural core of a group of important metabolites, that is, inositol phosphates and inositol phospholipids, that are involved in numerous

important biological processes including cellular signal transduction, membrane transport, protein anchoring, and cytoskeletal regulation.¹⁻⁴ Specifically, phosphatidylinositols, which constitute approximately 1% of the phospholipids in cell membranes, are selectively phosphorylated by multiple kinases at the C-3, C-4 and C-5 positions to generate a number of endogenous phosphatidylinositol phosphates which are in turn converted into various inositol phosphates differing for the phosphorylation pattern of the inositol ring.^{3,5}

Concentrations of inositol derivatives in biological systems are very low, thus strongly limiting their analytical detection and the isolation from natural sources in useful amounts to fully elucidate their physiological functions. For this reason, numerous synthetic efforts are still in progress to prepare biologically relevant inositol phosphates

[This article is part of the Special issue: Chirality in Pharmaceutical Research and Development. See the first articles for this special issue previously published in Volumes 34:3, 34:6, and 34:7. More special articles will be found in this issue as well as in those to come.]

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. *Chirality* published by Wiley Periodicals LLC.

and inositol phospholipids as well as many of their analogs to be used as chemical probes in biological studies.^{5–7}

Most of the synthetic routes to inositol phosphates and phospholipids commenced from *myo*-inositol, a cheap and readily available starting material, and involve properly protected chiral derivatives of *myo*-inositol as key intermediates. Such derivatives have been prepared both by resolution of *myo*-inositol (a *meso* compound) and by stereoselective synthesis using chemical and/or enzymatic approaches and exploiting many selective protection and deprotection schemes of inositol hydroxyl groups.^{8–12}

Among the known inositol phosphates, glycerophosphoinositols have recently attracted much attention due to their distinctive biological activity.¹³ These water-soluble ubiquitous cellular metabolites, produced through the deacylation of the membrane phosphoinositides by receptor-activated cytosolic phospholipase A2 α ,¹³ include non-phosphorylated *sn*-glycero-3-phosphoinositol (glycerophosphoinositol [GPI]) and its phosphorylated derivatives glycerophosphoinositol 4-phosphate and glycerophosphoinositol 4,5-bisphosphate. GPI has been found to play a role as an endogenous mediator in the inflammatory response, being part of a negative feedback loop that inhibits the *de novo* synthesis of pro-inflammatory and pro-thrombotic compounds. The anti-inflammatory activity of exogenous GPI has been investigated both *in vitro* and in an *in vivo* model in comparison with dexamethasone, showing that GPI parallels the anti-inflammatory effect of the corticosteroid drug.¹³ Moreover, the anti-inflammatory effect of GPI in counteracting blood-brain barrier (BBB) failure has been found at lower doses than dexamethasone and without cytotoxic effects, thus suggesting the use of GPI as a natural anti-inflammatory agent and a “BBB enhancer” for neurodegenerative diseases such as multiple sclerosis and Alzheimer’s dementia.¹⁴

As a part of our studies on the synthesis of GPI, here we report the chemical synthesis and the characterization of optically active 2-*O*-acetyl-3,4,5,6-tetra-*O*-benzyl-*D*-*myo*-inosityl diphenylphosphate (**6**), a new useful building block for the synthesis of inositol phosphates and phospholipids.

2 | MATERIALS AND METHODS

All solvents and reagents were purchased from Sigma-Aldrich and Scharlab and used without further purification. Analytical TLC was performed on silica gel F₂₅₄ pre-coated aluminum sheets (0.2-mm layer, Merck). Silica gel 60, 40–63 μm (Merck, Darmstadt, Germany) was used for flash column chromatography. ¹H, ¹³C, and ³¹P NMR spectra were recorded at 400.13, 100.61, and 161.96 Hz, respectively, on a Bruker AVANCE 400 (Bruker, Karlsruhe, Germany) spectrometer equipped with the

TOPSPIN software package (Bruker, Karlsruhe, Germany) at 300 K, unless stated otherwise. MestReNova (v. 14.2) from Mestrelab Research was used for NMR processing. ¹H and ¹³C chemical shifts (δ) are given in parts per million and are referenced to the solvent signal (δ_{H} 7.26– δ_{C} 77.16 ppm from tetramethylsilane [TMS] for CDCl₃). ³¹P chemical shifts (δ) are given in parts per million and are referenced to standard H₃PO₄ (aq) 85% (0 ppm). ¹H NMR signals were assigned with the aid of ¹H–¹H correlation spectroscopy (¹H–¹H COSY). ¹³C NMR APT (attached proton test) signals were assigned by ¹H–¹³C correlation experiments (heteronuclear multiple quantum correlation spectroscopy [HSQC] and heteronuclear multiple bond correlation spectroscopy [HMBC]). Optical rotations were measured on a Jasco P-1030 polarimeter (LabX, Midland, Ontario, Canada). Electrospray ionization mass spectra (ESI-MS) were recorded on the Thermo Finnigan LCQ Advantage spectrometer (Hemel Hempstead, Hertfordshire, UK). For NMR and MS spectra, see Supporting Information.

3 | SYNTHESIS OF 2-*O*-ACETYL-3,4,5,6-TETRA-*O*-BENZYL-*D*-*MYO*-INOSITYL DIPHENYLPHOSPHATE (**6**) FROM *MYO*-INOSITOL (**1**)

D-1,2-*O*-(1-1,7,7-Trimethyl[2.2.1]bicyclohept-2-ylidene)-*myo*-inositol (**2**). *L*-Camphor dimethyl acetal (**7**) (220 mg, 1.11 mmol) and PTSA (8 mg, 0.04 mmol) were added to a dispersion of dry *myo*-inositol (**1**, 100 mg, 0.56 mmol) in anhydrous DMSO (2.0 mL) under inert atmosphere. The resulting mixture was stirred at 55°C for 4 h until complete dissolution of the substrate was observed. The reaction was cooled to room temperature, neutralized with Et₃N, and concentrated under reduced pressure. The residue was suspended in a mixture of CHCl₃/MeOH/H₂O (50:5:1, 10 mL), PTSA (5 mg) was added, and the resulting mixture was stirred at room temperature overnight. After neutralization with Et₃N, the resulting precipitate was filtered and washed with CHCl₃. The resulting crude was purified by flash chromatography (CHCl₃/MeOH 9:1, *R*_f 0.22), and **2** was obtained as the major component of a mixture of diastereoisomers, which was used in the next reaction without further purification (90 mg, 0.29 mmol, 49%).

¹H NMR (400 MHz, DMSO-*d*₆, δ) *major isomer*: 4.81–4.74 (m, 3H, OH), 4.69 (d, *J* = 4.1 Hz, 1H, OH), 4.09 (dd, *J* = 5.7, 4.1 Hz, 1H, CH sugar), 3.66 (t, *J* = 7.0, 5.6 Hz, 1H, CH sugar), 3.52 (dt, *J* = 8.9, 4.3 Hz, 1H, CH sugar), 3.31–3.15 (m, 2H, 2 \times CH sugar), 2.93 (td, *J* = 9.4, 3.9 Hz, 1H, CH sugar), 2.00–1.84 (m, 2H, 2 \times CH₂ camphor), 1.72–1.61 (m, 2H, CH and CH₂ camphor), 1.40 (d,

$J = 12.8$ Hz, 1H, CH₂ camphor), 1.31 (td, $J = 13.0, 12.4, 4.9$ Hz, 1H, CH₂ camphor), 1.18–1.08 (m, 1H, CH₂ camphor), 0.97 (s, 3H, CH₃), 0.83 (2, 3H, CH₃), 0.77 (s, 3H, CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆, δ) 116.4 (Cq camphor), 77.1 (CH sugar), 76.7 (CH sugar), 76.1 (CH sugar), 74.4 (CH sugar), 72.3 (CH sugar), 70.2 (CH sugar), 51.6 (Cq camphor), 47.9 (Cq camphor), 45.7 (CH₂ camphor), 45.1 (CH camphor), 29.6 (CH₂ camphor), 27.3 (CH₂ camphor), 21.0 (CH₃ camphor), 20.8 (CH₃ camphor), 10.2 (CH₃ camphor); MS (ESI, m/z): $[M - H]^-$ calcd for C₁₆H₂₆O₆, 313.17; found, 313.04.

D-3,4,5,6-Tetra-*O*-benzyl-1,2-*O*-(L-1,7,7-trimethyl[2.2.1]bicyclohept-2-ylidene)-*myo*-inositol (**3**). NaH (60% dispersion in mineral oil, 2.46 g, 61.50 mmol) was added in one portion to a solution of **2** (1.20 g, 3.82 mmol) in dry DMF (50 mL) at 0°C under inert atmosphere. After stirring at 0°C for 30 min, BnBr (2.8 mL, 23.54 mmol) was added, and the mixture was stirred at room temperature for 24 h. The reaction was quenched first with MeOH and then with H₂O under vigorous stirring at 0°C. After evaporation of the solvent under reduced pressure, the residue was dissolved in AcOEt (30 mL) and washed with H₂O (2 × 15 mL) and brine (1 × 10 mL). The organic layer was dried over Na₂SO₄ and evaporated under reduced pressure. The resulting crude was purified by flash chromatography (*n*-hexane/AcOEt 9:1, R_f 0.31) to get **3** as a light-yellow oil (2.17 g, 3.22 mmol, 84%).

¹H NMR (400 MHz, CDCl₃, δ) 7.45–7.28 (m, 20H, 4 × Ph), 4.95 (d, $J = 11.4$ Hz, 1H, CH₂Ph), 4.87–4.72 (m, 7H, CH₂Ph), 4.35 (dd, $J = 6.2, 4.1$ Hz, 1H, CH sugar), 4.01 (dd, $J = 7.1, 6.2$ Hz, 1H, CH sugar), 3.88 (t, $J = 8.2$ Hz, 1H, CH sugar), 3.84–3.75 (m, 2H, 2 × CH sugar), 3.48 (dd, $J = 9.6, 7.9$ Hz, 1H, CH sugar), 2.07–1.94 (m, 2H, 2 × CH₂ camphor), 1.83–1.73 (m, 2H, CH, and CH₂ camphor), 1.53 (d, $J = 12.9$ Hz, 1H, CH₂ camphor), 1.43 (td, $J = 12.6, 4.9$ Hz, 1H, CH₂ camphor), 1.37–1.25 (m, 1H, CH₂ camphor), 1.13 (s, 3H, CH₃ camphor), 0.92 (s, 3H, CH₃ camphor), 0.90 (s, 3H, CH₃ camphor); ¹³C NMR (100 MHz, CDCl₃, δ) 138.8, 138.7, 138.5 (4 × Cq phenyl), 128.4, 128.3, 128.1, 128.0, 127.8, 127.7, 127.59, 127.55, 127.5 (20 × CH phenyl), 117.7 (Cq camphor), 83.3 (CH sugar), 82.2 (CH sugar), 80.8 (CH sugar), 77.4 (CH sugar), 76.3 (CH sugar), 75.2 (CH₂Ph), 75.0 (CH₂Ph), 74.0 (CH₂Ph), 73.7 (CH sugar), 72.5 (CH₂Ph), 51.6 (Cq camphor), 48.0 (Cq camphor), 45.2 (CH camphor), 45.0 (CH₂ camphor), 29.8 (CH₂ camphor), 27.1 (CH₂ camphor), 20.7 (CH₃ camphor), 20.4 (CH₃ camphor), 10.2 (CH₃ camphor); MS (ESI, m/z): $[M + Na]^+$ calcd for C₄₄H₅₀O₆Na, 697.35; found, 697.14.

D-3,4,5,6-Tetra-*O*-benzyl-*myo*-inositol (**4**). A solution of **3** (890 mg, 1.32 mmol) in AcOH (80% in H₂O v/v, 45 mL) was stirred at 100°C for 2 h. The solvent was

removed under reduced pressure, and *n*-hexane (15 mL) was added to the residue to precipitate **4** as an off-white powder (503 mg, 0.93 mmol, 71%).

$[\alpha]_D^{20} = -0.23$ deg cm³ g⁻¹ dm⁻¹ ($c = 1.00$ g cm⁻³ in CHCl₃); ¹H NMR (400 MHz, DMSO-*d*₆, δ) 7.41–7.22 (m, 20H, 4 × Ph), 5.00 (d, $J = 4.0$ Hz, 1H, OH), 4.89 (d, $J = 2.4$ Hz, 1H, OH), 4.87 (d, $J = 6.8$ Hz, 1H, CH₂Ph), 4.82 (d, $J = 11.1$ Hz, 1H, CH₂Ph), 4.76 (br s, 2H, CH₂Ph), 4.72 (br s, 2H, CH₂Ph), 4.71–4.68 (m, 1H, CH₂Ph), 4.54 (d, $J = 11.9$ Hz, 1H, CH₂Ph), 4.05 (q, $J = 2.8$ Hz, 1H, CH sugar), 3.81 (t, $J = 9.5$ Hz, 1H, CH sugar), 3.67 (t, $J = 9.5$ Hz, 1H, CH sugar), 3.49–3.44 (m, 2H, 2 × CH sugar), 3.40 (t, $J = 9.3$ Hz, 1H, CH sugar); ¹³C NMR (100 MHz, DMSO-*d*₆, δ) 139.9, 139.52, 139.48, 139.4 (4 × Cq phenyl), 128.6, 128.53, 128.45, 127.98, 127.95, 127.8, 127.72, 127.69, 127.6 (20CH × phenyl), 83.2 (CH sugar), 82.3 (CH sugar), 81.6 (CH sugar), 80.5 (CH sugar), 75.1, 75.0, 74.6 (3 × CH₂Ph), 72.0 (CH sugar), 71.1 (CH₂Ph), 69.8 (CH sugar); MS (ESI, m/z): $[M + Na]^+$ calcd for C₃₄H₃₆O₆Na, 563.24; found, 563.15.

2-*O*-Acetyl-3,4,5,6-tetra-*O*-benzyl-D-*myo*-inositol (**5**). A solution of **4** (300 mg, 0.55 mmol), PTSA·H₂O (10 mg, 0.05 mmol) and trimethyl orthoacetate (0.30 mL, 2.74 mmol) in acetonitrile (20 mL) was stirred at room temperature for 2 h. The reaction was cooled to -40°C and H₂O (0.30 mL) was added; then the mixture was stirred at -40°C for 4 h, neutralized with pyridine and concentrated under reduced pressure. The residue was dissolved in AcOEt (20 mL), washed with H₂O (2 × 10 mL), dried over Na₂SO₄ and evaporated under reduced pressure. The resulting crude was purified by flash chromatography (*n*-hexane/EtOAc 8:2, R_f 0.30) to get **5** as a colorless oil (290 mg, 0.50 mmol, 91%).

$[\alpha]_D^{20} = -1.78$ deg cm³ g⁻¹ dm⁻¹ ($c = 2.00$ g cm⁻³ in CHCl₃); ¹H NMR (400 MHz, CDCl₃, δ) 7.41–7.28 (m, 20H, 4 × Ph), 5.75 (t, $J = 2.8$ Hz, 1H, CH sugar), 5.04–4.95 (m, 3H, 3 × CH₂Ph), 4.87 (d, $J = 10.6$ Hz, 1H, CH₂Ph), 4.83 (d, $J = 10.7$ Hz, 1H, CH₂Ph), 4.79 (d, $J = 5.0$ Hz, 1H, CH₂Ph), 4.76 (d, $J = 5.1$ Hz, 1H, CH₂Ph), 4.54 (d, $J = 11.2$ Hz, 1H, CH₂Ph), 3.92 (t, $J = 9.5$ Hz, 1H, CH sugar), 3.82 (t, $J = 9.6$ Hz, 1H, CH sugar), 3.64 (br d, $J = 9.6$ Hz, 1H, CH sugar), 3.60–3.54 (m, 2H, 2 × CH sugar), 2.34 (br s, 1H, OH), 2.18 (s, 3H, CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆, δ) 170.5 (C=O), 138.6, 138.3, 137.6 (4 × Cq phenyl), 128.7, 128.5, 128.4, 128.4, 128.3, 128.0, 128.0, 127.9, 127.8, 127.7 (4 × CH phenyl), 83.3 (CH sugar), 82.0 (CH sugar), 81.5 (CH sugar), 78.5 (CH sugar), 76.0, 76.0, 75.6, 72.2 (4 × CH₂Ph), 70.2 (CH sugar), 69.3 (CH sugar), 21.1 (CH₃); MS (ESI, m/z): $[M + Na]^+$ calcd for C₃₆H₃₈O₇Na, 605.25; found, 605.53.

2-*O*-Acetyl-3,4,5,6-tetra-*O*-benzyl-*D*-*myo*-inosityl diphenylphosphate (**6**). DMAP (2.3 mg, 0.02 mmol), Et₃N (210 μL, 152 mg, 1.50 mmol), and DPC (160 μL, 207 mg, 0.77 mmol) were added to a solution of **5** (107 mg, 0.18 mmol) in CH₂Cl₂ (10 mL), and the resulting mixture was stirred at room temperature for 24 h. The reaction was washed with H₂O (20 mL) and brine (20 mL). The organic phase was dried over Na₂SO₄ and concentrated under reduced pressure to get a yellow oil crude, which was purified by flash chromatography (hexane/AcOEt 8:2, R_f 0.31) to get **6** as a light-yellow oil (105 mg, 0.13 mmol, 70%).

[α]_D²⁰ = +0.95 deg cm³ g⁻¹ dm⁻¹ (*c* = 1.53 g cm⁻³ in CHCl₃); ¹H NMR (400 MHz, CDCl₃, δ) 7.43–7.06 (m, 30H, 2 × Ph and 4 × Bn), 5.98 (t, *J* = 2.8 Hz, 1H, H-2), 4.94–4.75 (m, 7H, CH₂Ph), 4.67 (ddd, *J* = 10.1, 8.4, 2.9 Hz, 1H, H-1), 4.47 (d, *J* = 10.9 Hz, 1H, CH₂Ph), 4.05 (t, *J* = 9.6 Hz, 1H, H-6), 3.87 (t, *J* = 9.5 Hz, 1H, H-4), 3.62–3.54 (m, 2H, H-3 and H-5), 2.11 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, δ) 169.4 (C=O), 150.5, 150.4 (2 × Ph), 138.5, 138.2, 138.1, 137.5 (4 × Bn), 129.8, 129.7, 128.5, 128.4, 128.4, 128.2, 128.0, 128.0, 127.9, 127.8, 127.7, 127.7, 127.5, 125.4, 125.3 (2 × Ph and 4 × Bn), 120.2, 120.0 (2 × Ph), 82.6 (C-5), 81.1 (C-4), 80.0 (C-6), 78.2 (C-3), 77.4 (C-1), 76.3, 76.0, 75.7, 72.4 (4 × CH₂Ph), 68.6 (C-2), 20.9 (CH₃); ³¹P NMR (162 MHz, CDCl₃, δ) –12.30; MS (ESI, *m/z*): [M + H]⁺ calcd for C₄₈H₄₈O₁₀P, 815.30; found, 815.24; [M + Na]⁺ calcd for C₄₈H₄₇O₁₀PNa, 837.28; found, 837.45; Anal. calcd for C₄₈H₄₇O₁₀P: C 70.75, H 5.81; found: C 69.99, H 6.20.

L-Camphor dimethyl acetal (**7**). The title compound was synthesized in 68% yield according to a procedure already reported in literature, with some modifications.¹⁵ In details, the crude was purified not by distillation but by flash chromatography (*n*-hexane-AcOEt 9:1, R_f 0.86).


¹H NMR (400 MHz, CDCl₃, δ) 3.11 (s, 3H, OCH₃), 3.08 (s, 3H, OCH₃), 2.14 (ddd, *J* = 12.9, 4.6, 3.0 Hz, 1H, CH₂), 1.74–1.61 (m, 3H, CH, and 2 × CH₂), 1.36–1.27 (m, 1H, 2 × CH₂), 1.17–1.11 (m, 1H, 2 × CH₂), 1.08 (d, *J* = 12.7 Hz, 1H, CH₂), 0.91 (s, 3H, CH₃), 0.87 (s, 3H, CH₃), 0.79 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, δ): 109.1 (C [OCH₃]₂), 53.0 (Cq), 50.2 (OCH₃), 49.9 (Cq), 47.2 (OCH₃), 44.3 (CH), 41.0 (CH₂), 29.3 (CH₂), 27.3 (CH₂), 20.8 (CH₃), 20.5 (CH₃), 12.4 (CH₃); MS (ESI, *m/z*): [M]⁺ calcd for C₁₂H₂₂O₂, 198.16; found, 198.07.

4 | RESULTS AND DISCUSSION

Several methods have been reported in the literature for the preparation of enantiopure *myo*-inositol derivatives by resolution of *myo*-inositol. Among them, we followed the methodology based on introduction of *D*- or *L*-camphor as chiral auxiliaries into the *myo*-inositol structure. Such an approach, first described by Bruzik et al.,^{8,9} results both in the desymmetrization of *myo*-inositol and in the regioselective protection of its hydroxyl groups in C-1 and C-2 positions.


As illustrated in Scheme 1, we adopted the procedure reported by Nkambule, with some modifications,¹⁰ to obtain 2-*O*-acetyl-3,4,5,6-tetra-*O*-benzyl-*D*-*myo*-inositol (**5**), which was then converted to enantiomerically pure 2-*O*-acetyl-3,4,5,6-tetra-*O*-benzyl-*D*-*myo*-inosityl diphenylphosphate (**6**). This strategy enabled us to synthesize the target molecule in five steps from *myo*-inositol (**1**) in an overall 19% yield.

More in details, **1** was transketalized by treatment with 2 equivalents of *L*-camphor dimethyl acetal (**7**, prepared by treatment of *L*-camphor with trimethyl orthoformate), and PTSA in dry DMSO at 55 °C. The selectivity of the reaction led to the formation of *cis*



SCHEME 1 Synthesis of 2-*O*-acetyl-3,4,5,6-tetra-*O*-benzyl-*D*-*myo*-inosityl diphenylphosphate (**6**) from *myo*-inositol (**1**).

monoacetal **2** as the major product in a complex mixture of diastereoisomers. The PTSA-catalyzed equilibration of the crude mixture allowed to further increase the amount of the desired isomer **2**, protected at 1 and 2 positions and having the *D* configuration. After precipitation in dichloromethane, the mixture containing **2** was directly treated with benzyl bromide and NaH in dry DMF to protect the remaining four hydroxyl groups as benzyl ethers to give **3**. The latter intermediate was easily purified from the traces of diastereoisomers generated in the previous step by flash chromatography. The chiral auxiliary was then removed with concentrated acetic acid (80% v/v solution in water) at 100°C, and the resulting crude product **4** was used in the next step without further purification.



SCHEME 2 Regioselective hydrolysis and opening of **8**.

The regioselective acetylation of **4** was carried out by treatment with trimethyl orthoacetate and PTSA in acetonitrile, followed by hydrolysis of the intermediate mixed orthoacetate (**8**) and purification by flash chromatography to get the key intermediate **5**. The different reactivity of the equatorially and axially oriented oxygens in **8** directs the hydrolytic opening of the dioxolane ring selectively at the C-1 position, thus allowing the retention of the protection on the adjacent moiety at C-2 (Scheme 2).^{16,17}

To complete the synthetic sequence, **5** was reacted with excess diphenyl phosphoryl chloride (DPC), a catalytic amount of 4-dimethylaminopyridine and triethylamine in dichloromethane, followed by simple aqueous workup and chromatographic purification to give the target product **6** in 70% yield.

2-*O*-Acetyl-3,4,5,6-tetra-*O*-benzyl-*D*-myoinosityl diphenylphosphate (**6**) was fully characterized by mono- and bidimensional NMR spectroscopy (¹H-NMR, COSY, HMBC, HSQC, ¹³C-NMR, ³¹P-NMR), ESI-MS and $[\alpha]_D^{20}$.

The ¹H-NMR spectrum of **6** recorded in CDCl₃ (Figure 1) showed the expected pattern of signals. In details, the typical signal of the equatorial proton H-2, usually located slightly downfield with respect to the others, is further shifted to 5.98 ppm. Similarly, the axial proton H-1 was also shifted downfield to 4.66 ppm with respect to the corresponding signal in *myo*-inositol (**1**).¹⁸




FIGURE 1 ¹H-NMR (400 MHz, CDCl₃) of **6** in the range 3.4–6.1 ppm

5 | CONCLUSION

To sum up, this short note reports the synthesis of 2-*O*-acetyl-3,4,5,6-tetra-*O*-benzyl-*D*-*myo*-inosityl diphenylphosphate (**6**), a new optically active inositol phosphate derivative that may be a useful building block for the synthesis of inositol phosphates and phospholipids such as the anti-inflammatory agent GPI. It is worth noting that, to the best of our knowledge, no chemical synthesis of GPI and its phosphorylated derivatives has been reported to date. Starting from **6**, GPI might be simply prepared by treatment with a properly protected glycerol synthon, followed by removal of all protective groups.²

ACKNOWLEDGMENTS

This research was funded by Cariplo Foundation and Innovhub-SSI (Italy), grant number ID 2017-0978 (call: "Integrated research on industrial biotechnologies and bioeconomy-joint Call 2017," project BIOCOSM). A special acknowledgement is due to Cariplo Foundation for supporting young researchers by this project (S.S., M.C., R.S.). Open Access Funding provided by Università degli Studi di Milano within the CRUI-CARE Agreement. [Correction added on 5 July 2022, after first online publication: CRUI funding statement has been added.]

CONFLICT OF INTEREST

The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available in the Supporting Information of this article.

ORCID

Marco Rabuffetti  <https://orcid.org/0000-0003-2089-1333>

REFERENCES

- Chhetri DR. *Myo*-Inositol and its derivatives: their emerging role in the treatment of human diseases. *Front Pharmacol*. 2019;10:1172. doi:10.3389/fphar.2019.01172
- Semproli R, Robescu MS, Cambò M, et al. Chemical and enzymatic approaches to esters of *sn*-glycero-3-phosphoric acid. *Eur J Org Chem*. 2021;2021(29):4027-4037. doi:10.1002/ejoc.202100235
- Michell RH. Inositol derivatives: evolution and functions. *Nat Rev Mol Cell Biol*. 2008;9(2):151-161. doi:10.1038/nrm2334
- Hanashima S, Yano Y, Murata M. Enantiomers of phospholipids and cholesterol: a key to decipher lipid-lipid interplay in membrane. *Chirality*. 2020;32(3):282-298. doi:10.1002/chir.23171
- Elliott TS, Nemeth J, Swain SA, Conway SJ. A synthesis of phosphatidylinositol. *Tetrahedron: Asymmetry*. 2009;20(24):2809-2813. doi:10.1016/j.tetasy.2009.11.026
- Conway SJ, Gardiner J, Grove SJA, et al. Synthesis and biological evaluation of phosphatidylinositol phosphate affinity probes. *Org Biomol Chem*. 2010;8(1):66-76. doi:10.1039/B913399B

- Waybright J, Huang W, Proctor A, Wang X, Allbritton NL, Zhang Q. Required hydrophobicity of fluorescent reporters for phosphatidylinositol family of lipid enzymes. *Anal Bioanal Chem*. 2017;409(29):6781-6789. doi:10.1007/s00216-017-0633-y
- Bruzik KS, Tsai M-D. Efficient and systematic syntheses of enantiomerically pure and regioselectively protected *myo*-inositols. *J Am Chem Soc*. 1992;114(16):6361-6374. doi:10.1021/ja00042a011
- Wewers W, Gillandt H, Traub HS. Advances in analysis and synthesis of *myo*-inositol-derivatives through resolution by crystallisation. *Tetrahedron: Asymmetry*. 2005;16(10):1723-1728. doi:10.1016/j.tetasy.2005.03.033
- Nkambule CM, Kwezi NW, Kufe HH, et al. Efficient regioselective protection of *myo*-inositol via facile protecting group migration. *Tetrahedron*. 2011;67(3):618-623. doi:10.1016/j.tet.2010.11.063
- Sayer LH, Florence GJ, Smith TK. A biocatalytic approach towards the stereoselective synthesis of protected inositols. *React Chem Eng*. 2017;2(1):44-49. doi:10.1039/C6RE00175K
- Ribeiro MFP, Pais KC, de Jesus BSM, et al. Lipase regioselective *O*-acetylations of a *myo*-inositol derivative: efficient desymmetrization of 1,3-di-*O*-benzyl-*myo*-inositol. *Eur J Org Chem*. 2018;2018(3):386-391. doi:10.1002/ejoc.201701417
- Vessichelli M, Mariggio S, Varone A, et al. The natural phosphoinositide derivative glycerophosphoinositol inhibits the lipopolysaccharide-induced inflammatory and thrombotic responses. *J Biol Chem*. 2017;292(31):12828-12841. doi:10.1074/jbc.M116.773861
- Cucullo L, Hallene K, Dini G, Toso RD, Janigro D. Glycerophosphoinositol and dexamethasone improve transendothelial electrical resistance in an in vitro study of the blood-brain barrier. *Brain Res*. 2004;997(2):147-151. doi:10.1016/j.brainres.2003.09.079
- Wiberg KB, Cunningham WC. Thermochemical studies of carbonyl reactions. 4. Enthalpies of hydrolysis of norbornyl ketals. *J Org Chem*. 1990;55(2):679-684. doi:10.1021/jo00289a051
- Flores-Mosquera M, Martin-Lomas M, Chiara JL. Regiocontrolled acylation of *myo*-inositol orthoformate. *Tetrahedron Lett*. 1998;39(28):5085-5088. doi:10.1016/S0040-4039(98)00911-3
- Sarmah MP, Shashidhar MS. Sulfonate protecting groups. Improved synthesis of *scyllo*-inositol and its orthoformate from *myo*-inositol. *Carbohydr Res*. 2003;338(9):999-1001. doi:10.1016/S0008-6215(03)00052-1
- Fujisawa T, Fujinaga S, Atomi H. An in vitro enzyme system for the production of *myo*-inositol from starch. *Appl Environ Microbiol*. 2017;83(16):e00550-17. doi:10.1128/AEM.00550-17

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Sangiorgio S, Cambò M, Semproli R, Ubiali D, Speranza G, Rabuffetti M. 2-*O*-Acetyl-3,4,5,6-tetra-*O*-benzyl-*D*-*myo*-inosityl diphenylphosphate: A new useful intermediate to inositol phosphate and phospholipids. *Chirality*. 2022;34(8):1038-1043. doi:10.1002/chir.23457